Skip to main content


You are here

SilcsBio, LLC Receives Phase II NIH SBIR Funding

Tuesday, July 12, 2016

Baltimore, Maryland: SilcsBio, LLC announced today a $1.3 million funding award from the National Institute of Health to develop new computer aided drug design (CADD) software. CADD software enables pharmaceutical companies to rapidly identify new drug opportunities and reduce the overall costs and time requirements to bring drugs to market.

“This funding will allow us to improve upon our already best in class accuracy and extend its use into protein-protein interactions.” states Dr. Alex MacKerell, Chief Science Officer of SilcsBio.

While CADD has been around for decades, SilcsBio uses a dramatically different approach that provides users with accurate drug design prediction and feedback capabilities that allow for rapid improvements in the way potential drugs interact with their protein and RNA targets.

Click here to read the entire press release.